Ken Griffin Rx Sight, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$50.42 - $64.29 $1.07 Million - $1.36 Million	-21,200 Reduced 53.13%	18,700 $1.13 Million
Q1 2024 May 15, 2024	BUY	$35.51 - $57.92 $223,713 - $364,896	6,300 Added 18.75%	39,900 $2.06 Million
Q4 2023 Feb 14, 2024	SELL	$20.91 - $40.9 $706,758 - $1.38 Million	-33,800 Reduced 50.15%	33,600 $1.35 Million
Q3 2023 Nov 14, 2023	BUY	$27.05 - $33.37 $1.17 Million - $1.45 Million	43,400 Added 180.83%	67,400 $1.88 Million
Q2 2023 Aug 14, 2023	BUY	$16.37 - $28.9 $3,274 - $5,780	200 Added 0.84%	24,000 $691,000
Q1 2023 May 15, 2023	BUY	$12.58 - $16.68 $47,804 - $63,384	3,800 Added 19.0%	23,800 $396,000
Q4 2022 Feb 14, 2023	BUY	$9.93 - $14.2 $198,600 - $284,000	20,000 New	20,000 $253,000

229

31.7M

57.8K

12.5K

Ticker RXST
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 27,638,900
Market Cap $1.51B
Description
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. T...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.